Cutler Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Cutler Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,400	Closed	-$5K	–	4982
2022 Q2	$5K	Sell	4,400 -1,300	-23%	-$9.54K	﹤0.01%	3681
2022 Q1	$11K	Buy	+5,700	New	+$40.3K	﹤0.01%	3528

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cutler Group's CPRX Position: Q2 2017 in Review

Cutler Group sold out of Catalyst Pharmaceutical (CPRX) in Q2 2017, closing a stake of 5,646 shares — an estimated $11K sold.

Cutler Group first reported a position in CPRX in Q4 2015 and held it in 6 quarters. The position peaked at $13K in Q4 2015. 69 funds tracked by Wall St. Rank hold CPRX as of Q2 2017.

Cutler Group reported no remaining Catalyst Pharmaceutical position as of Q2 2017 after selling out during the quarter.
Cutler Group sold 5,646 Catalyst Pharmaceutical shares in Q2 2017, an estimated $11K.
Cutler Group first reported a position in Catalyst Pharmaceutical in Q4 2015 and held it in 6 quarters.
Cutler Group's Catalyst Pharmaceutical position peaked at $13K in Q4 2015.
69 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2017.

Based on Cutler Group's 13F filing for Q2 2017, filed 11 Jul 2017.